Preoperative prediction of microvascular invasion of hepatocellular carcinoma using 18F-FDG PET/CT: a multicenter retrospective cohort study

Seung Hyup Hyun, Jae Seon Eo, Bong Il Song, Jeong Won Lee, Sae Jung Na, Il Ki Hong, Jin Kyoung Oh, Yong An Chung, Tae Sung Kim, Mijin Yun

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: The aim of this study was to assess the potential of tumor 18F-fluorodeoxyglucose (FDG) avidity as a preoperative imaging biomarker for the prediction of microvascular invasion (MVI) of hepatocellular carcinoma (HCC). Methods: One hundred and fifty-eight patients diagnosed with Barcelona Clinic Liver Cancer stages 0 or A HCC (median age, 57 years; interquartile range, 50–64 years) who underwent 18F-FDG positron emission tomography with computed tomography (PET/CT) before curative surgery at seven university hospitals were included. Tumor FDG avidity was measured by tumor-to-normal liver standardized uptake value ratio (TLR) of the primary tumor on FDG PET/CT imaging. Logistic regression analysis was performed to identify significant parameters associated with MVI. The predictive performance of TLR and other clinical variables was assessed using receiver operating characteristic (ROC) curve analysis. Results: MVI was present in 76 of 158 patients with HCCs (48.1%). Multivariable logistic regression analysis revealed that TLR, serum alpha-fetoprotein (AFP) level, and tumor size were significantly associated with the presence of MVI (P < 0.001). Multinodularity was not significantly associated with MVI (P = 0.563). The area under the ROC curve (AUC) for predicting the presence of MVI was best with TLR (AUC = 0.704), followed by tumor size (AUC = 0.685) and AFP (AUC = 0.670). We were able to build an improved prediction model combining TLR, tumor size, and AFP by using multivariable logistic regression modeling (AUC = 0.756). Conclusions: Tumor FDG avidity measured by TLR on FDG PET/CT is a preoperative imaging biomarker for the prediction of MVI in patients with HCC.

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
DOIs
Publication statusAccepted/In press - 2017 Nov 22

Fingerprint

Fluorodeoxyglucose F18
Hepatocellular Carcinoma
Cohort Studies
Retrospective Studies
ROC Curve
Area Under Curve
Neoplasms
alpha-Fetoproteins
Logistic Models
Biomarkers
Regression Analysis
Positron Emission Tomography Computed Tomography
Liver Neoplasms
Liver
Serum

Keywords

  • FDG PET/CT
  • Hepatocellular carcinoma
  • Microvascular invasion
  • Multicenter trial
  • Standardized uptake value

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Preoperative prediction of microvascular invasion of hepatocellular carcinoma using 18F-FDG PET/CT : a multicenter retrospective cohort study. / Hyun, Seung Hyup; Eo, Jae Seon; Song, Bong Il; Lee, Jeong Won; Na, Sae Jung; Hong, Il Ki; Oh, Jin Kyoung; Chung, Yong An; Kim, Tae Sung; Yun, Mijin.

In: European Journal of Nuclear Medicine and Molecular Imaging, 22.11.2017, p. 1-7.

Research output: Contribution to journalArticle

Hyun, Seung Hyup ; Eo, Jae Seon ; Song, Bong Il ; Lee, Jeong Won ; Na, Sae Jung ; Hong, Il Ki ; Oh, Jin Kyoung ; Chung, Yong An ; Kim, Tae Sung ; Yun, Mijin. / Preoperative prediction of microvascular invasion of hepatocellular carcinoma using 18F-FDG PET/CT : a multicenter retrospective cohort study. In: European Journal of Nuclear Medicine and Molecular Imaging. 2017 ; pp. 1-7.
@article{49a1def487d247ee99bf7b2691b73cf3,
title = "Preoperative prediction of microvascular invasion of hepatocellular carcinoma using 18F-FDG PET/CT: a multicenter retrospective cohort study",
abstract = "Purpose: The aim of this study was to assess the potential of tumor 18F-fluorodeoxyglucose (FDG) avidity as a preoperative imaging biomarker for the prediction of microvascular invasion (MVI) of hepatocellular carcinoma (HCC). Methods: One hundred and fifty-eight patients diagnosed with Barcelona Clinic Liver Cancer stages 0 or A HCC (median age, 57 years; interquartile range, 50–64 years) who underwent 18F-FDG positron emission tomography with computed tomography (PET/CT) before curative surgery at seven university hospitals were included. Tumor FDG avidity was measured by tumor-to-normal liver standardized uptake value ratio (TLR) of the primary tumor on FDG PET/CT imaging. Logistic regression analysis was performed to identify significant parameters associated with MVI. The predictive performance of TLR and other clinical variables was assessed using receiver operating characteristic (ROC) curve analysis. Results: MVI was present in 76 of 158 patients with HCCs (48.1{\%}). Multivariable logistic regression analysis revealed that TLR, serum alpha-fetoprotein (AFP) level, and tumor size were significantly associated with the presence of MVI (P < 0.001). Multinodularity was not significantly associated with MVI (P = 0.563). The area under the ROC curve (AUC) for predicting the presence of MVI was best with TLR (AUC = 0.704), followed by tumor size (AUC = 0.685) and AFP (AUC = 0.670). We were able to build an improved prediction model combining TLR, tumor size, and AFP by using multivariable logistic regression modeling (AUC = 0.756). Conclusions: Tumor FDG avidity measured by TLR on FDG PET/CT is a preoperative imaging biomarker for the prediction of MVI in patients with HCC.",
keywords = "FDG PET/CT, Hepatocellular carcinoma, Microvascular invasion, Multicenter trial, Standardized uptake value",
author = "Hyun, {Seung Hyup} and Eo, {Jae Seon} and Song, {Bong Il} and Lee, {Jeong Won} and Na, {Sae Jung} and Hong, {Il Ki} and Oh, {Jin Kyoung} and Chung, {Yong An} and Kim, {Tae Sung} and Mijin Yun",
year = "2017",
month = "11",
day = "22",
doi = "10.1007/s00259-017-3880-4",
language = "English",
pages = "1--7",
journal = "European Journal of Nuclear Medicine and Molecular Imaging",
issn = "1619-7070",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Preoperative prediction of microvascular invasion of hepatocellular carcinoma using 18F-FDG PET/CT

T2 - a multicenter retrospective cohort study

AU - Hyun, Seung Hyup

AU - Eo, Jae Seon

AU - Song, Bong Il

AU - Lee, Jeong Won

AU - Na, Sae Jung

AU - Hong, Il Ki

AU - Oh, Jin Kyoung

AU - Chung, Yong An

AU - Kim, Tae Sung

AU - Yun, Mijin

PY - 2017/11/22

Y1 - 2017/11/22

N2 - Purpose: The aim of this study was to assess the potential of tumor 18F-fluorodeoxyglucose (FDG) avidity as a preoperative imaging biomarker for the prediction of microvascular invasion (MVI) of hepatocellular carcinoma (HCC). Methods: One hundred and fifty-eight patients diagnosed with Barcelona Clinic Liver Cancer stages 0 or A HCC (median age, 57 years; interquartile range, 50–64 years) who underwent 18F-FDG positron emission tomography with computed tomography (PET/CT) before curative surgery at seven university hospitals were included. Tumor FDG avidity was measured by tumor-to-normal liver standardized uptake value ratio (TLR) of the primary tumor on FDG PET/CT imaging. Logistic regression analysis was performed to identify significant parameters associated with MVI. The predictive performance of TLR and other clinical variables was assessed using receiver operating characteristic (ROC) curve analysis. Results: MVI was present in 76 of 158 patients with HCCs (48.1%). Multivariable logistic regression analysis revealed that TLR, serum alpha-fetoprotein (AFP) level, and tumor size were significantly associated with the presence of MVI (P < 0.001). Multinodularity was not significantly associated with MVI (P = 0.563). The area under the ROC curve (AUC) for predicting the presence of MVI was best with TLR (AUC = 0.704), followed by tumor size (AUC = 0.685) and AFP (AUC = 0.670). We were able to build an improved prediction model combining TLR, tumor size, and AFP by using multivariable logistic regression modeling (AUC = 0.756). Conclusions: Tumor FDG avidity measured by TLR on FDG PET/CT is a preoperative imaging biomarker for the prediction of MVI in patients with HCC.

AB - Purpose: The aim of this study was to assess the potential of tumor 18F-fluorodeoxyglucose (FDG) avidity as a preoperative imaging biomarker for the prediction of microvascular invasion (MVI) of hepatocellular carcinoma (HCC). Methods: One hundred and fifty-eight patients diagnosed with Barcelona Clinic Liver Cancer stages 0 or A HCC (median age, 57 years; interquartile range, 50–64 years) who underwent 18F-FDG positron emission tomography with computed tomography (PET/CT) before curative surgery at seven university hospitals were included. Tumor FDG avidity was measured by tumor-to-normal liver standardized uptake value ratio (TLR) of the primary tumor on FDG PET/CT imaging. Logistic regression analysis was performed to identify significant parameters associated with MVI. The predictive performance of TLR and other clinical variables was assessed using receiver operating characteristic (ROC) curve analysis. Results: MVI was present in 76 of 158 patients with HCCs (48.1%). Multivariable logistic regression analysis revealed that TLR, serum alpha-fetoprotein (AFP) level, and tumor size were significantly associated with the presence of MVI (P < 0.001). Multinodularity was not significantly associated with MVI (P = 0.563). The area under the ROC curve (AUC) for predicting the presence of MVI was best with TLR (AUC = 0.704), followed by tumor size (AUC = 0.685) and AFP (AUC = 0.670). We were able to build an improved prediction model combining TLR, tumor size, and AFP by using multivariable logistic regression modeling (AUC = 0.756). Conclusions: Tumor FDG avidity measured by TLR on FDG PET/CT is a preoperative imaging biomarker for the prediction of MVI in patients with HCC.

KW - FDG PET/CT

KW - Hepatocellular carcinoma

KW - Microvascular invasion

KW - Multicenter trial

KW - Standardized uptake value

UR - http://www.scopus.com/inward/record.url?scp=85034655633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034655633&partnerID=8YFLogxK

U2 - 10.1007/s00259-017-3880-4

DO - 10.1007/s00259-017-3880-4

M3 - Article

C2 - 29167923

AN - SCOPUS:85034655633

SP - 1

EP - 7

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

SN - 1619-7070

ER -